Toronto, Canada, 12 December 2019:
Toronto Innovation Acceleration Partners ("TIAP") announced today the launch of a new project developed under the BRIDGE LAB150, a partnership between Evotec SE and TIAP. The project will be focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member, and aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners.

The low survival rates of three of the four most lethal cancers in North America - pancreatic, colorectal and lung - are associated with KRAS mutations, a well-established cancer driver. Although there is an urgent need for KRAS-targeting therapeutics, so far there has been a lack of clinically available drugs as oncogenic KRAS is very difficult to target directly.

LAB150 accelerates academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms and expertise. For further information on the new LAB150 projects, click here for LAB150's newsroom.